Strategic Collaboration Shasqi is actively expanding partnerships, including a recent collaboration expansion with Johnson & Johnson Enterprise Innovation, presenting a clear sales opportunity to position CAPAC partnerships for larger pharma alliances and co-development deals.

Clinical Pipeline Readiness With lead asset targeting CEACAM5 binder and MMAE protodrug moving to the clinic in Spring 2027, there is a near-term window to offer specialized click-activated libraries, protodrug optimization services, or companion diagnostic tools to accelerate clinical timelines.

Financial Momentum Shasqi has secured substantial funding totaling around 65 million dollars across multiple rounds, suggesting the company is in growth mode and may be receptive to strategic financing, grant collaborations, or value-adding investments tied to CAPAC platform expansion.

Clinical Leadership Key hires in leadership such as Chief Medical Officer and Chief Financial Officer, along with experienced executives, indicate a priority on robust clinical development and governance; this creates opportunities to offer CRO partnerships, advisory services, or clinical operation support solutions.

Technology & Data Shasqi’s tech stack and use of data-driven platforms imply readiness for partnerships in data analytics, pharmacodynamics modeling, and digital CRO/tech-enabled trial management to enhance the CAPAC platform’s efficiency and decision-making.